Based: Cambridge, MA
Investors: Fidelity Biosciences, Maverick Capital, Morgan Stanley Private Equity, Paperboy Ventures, Polaris Venture Partners, Sigma Capital, Undisclosed Venture Firm, Venrock Associates
Scoop: Gastrointestinal and cardiovascular therapies make up the focus of Microbia's business. It is developing linaclotide, a first-in-class compound for constipation-predominant irritable bowel syndrome and other gastrointestinal problems. Linaclotide is orally delivered. In 2007 Microbia landed a $330 million deal with Forest Laboratories for the Phase II drug. The company is also developing a cholesterol absorption inhibitor. Microbia was a 2006 Fierce 15 company.